Abstracts tagged "Autoantibody(ies)"

Abstract Number: 2636 • ACR Convergence 2025
Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
Raj Sengupta¹, Anthony Marotta², Walter P. Maksymowych³, Charlotte Cavill⁴, Stephen Bleakley² and Norma Biln⁵, ¹Royal National Hospital for Rheumatic Diseases, Bath, England, United Kingdom, ²Augurex Life Sciences Corp, Vancouver, BC, Canada, ³Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ⁴Royal United Hospitals Bath NHS Foundation Trust, Bath, England, United Kingdom, ⁵Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: People with axial spondyloarthritis (axSpA), typically present with persistent back pain and experience up to a 10-year diagnostic delay that may lead to irreversible…
Abstract Number: 0008 • ACR Convergence 2025
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
Julia Manasson¹, Liliana Sanmarco², Alex Pellerin², Maria Cecilia Ramello², Agustin Plasencia², Jordan Anderson², Tobias Green², Andita Newton², Ryan Peckner², Yi Xing², Heather Vital³, Nathan Higginson-Scott², John Sundy⁴, Kevin L. Otipoby² and Ivan Mascanfroni², ¹Seismic Therapeutic, New York, NY, ²Seismic Therapeutic, Watertown, MA, ³Seismic Therapeutic, Lexington, MA, ⁴Seismic Therapeutic, Durham, NC
Background/Purpose: Pathogenic autoantibodies are key effectors of inflammation, promoting tissue damage in autoantibody-mediated diseases such as inflammatory myopathies, lupus nephritis, Sjogren’s syndrome, antiphospholipid syndrome, and…
Abstract Number: 0296 • ACR Convergence 2025
Aggregation of HARS1 and internalized antibodies in muscle biopsies of patients with antisynthetase syndrome and anti-Jo1(HARS) autoantibodies
maria Casal-Dominguez¹, Iago Pinal Fernandez², Katherine Pak², Travis Kinder¹, Jon Musai¹, Ana Matas-Garcia³, Gloria Garrabou⁴, Iban aldecoa⁵, Albert Selva-O´callaghan⁶, José Milisenda⁷ and Andrew Mammen⁸, ¹National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ³Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, Spain, ⁴Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain., Barcelona, ⁵Pathology, Neurological Tissue Bank. Hospital Clinic of Barcelona-CDB-IDIBAPS/FCRB-University of Barcelona, Barcelona, Spain., Barcelona, ⁶Systemic Autoimmune Disease Section, Vall d'Hebron Institute of Research, Barcelona, Spain, Barcelona, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIH, Bethesda, MD
Background/Purpose: Autoimmune inflammatory myopathies (IMs) comprise a diverse group of diseases that primarily affect the muscles and often involve the lungs, skin, and joints. Among…
Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Xueting Yuan¹, Menghua Cai², Lu Gao², Chen Yu³, Jia Shi⁴, Yinghui Li², jiuliang Zhao¹, Dong Xu⁵, Chaojun Hu¹, Mengtao Li⁶, Xiaofeng Zeng⁷, jianmin Zhang² and Qian Wang⁶, ¹Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ²Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China (People's Republic), ³Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁴University of Washington, Seattle, WA, ⁵Peking Union Medical College Hospital, Dong Cheng District, China (People's Republic), ⁶Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁷Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, Beijing, China (People's Republic)
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…
Abstract Number: 0953 • ACR Convergence 2025
NMDAR Autoantibody-Induced Neuronal Damage in the Amygdala Mediates Mood and Anxiety Disorders in a Model of Neuropsychiatric Lupus
Rachel Weissman-Tsukamoto¹, Bruce Volpe¹, Zaide Ibic¹, Kaitlin Carroll², An Vo¹, Czeslawa Kowal¹ and Betty Diamond³, ¹Feinstein Institute of Molecular Medicine, Manhasset, NY, ²Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, ³The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease characterized by aberrant production of autoantibodies and chronic inflammation. Up to 80% of individuals with…
Abstract Number: 1488 • ACR Convergence 2025
Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis
Jessica Dai¹, Peter Izmirly², Jill Buyon³ and H Michael Belmont⁴, ¹New York University Grossman School of Medicine, Tenafly, NJ, ²New York University Grossman School of Medicine, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY
Background/Purpose: Anti-dsDNA antibodies are a key diagnostic marker of systemic lupus erythematosus (SLE), often associated with active disease. Its presence is detected using various commercial…
Abstract Number: 2027 • ACR Convergence 2025
Development of a multi-disease panel for autoimmune diseases
Charlotta Preger, Maria Aspenberg, Metta Berenpas, Peter Nilsson and Elisa Pin, Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
Background/Purpose: Autoantibodies serve as important biomarkers for diagnosing autoimmune diseases. However, current clinical assays for their detection often face challenges, such as uncertainty about the…
Abstract Number: 2414 • ACR Convergence 2025
Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
Alice Horisberger¹, Emily Oakes², Eilish Dillon³, Ifeoluwakiisi Adejoorin², Julia Caldropoli³, Kathryne Marks², Takanori Sasaki³, Farbod Moghaddam⁴, Paul Sciore⁵, Marvin J. Fritzler⁶, Deepak Rao², May Choi⁷ and Karen H. Costenbader⁸, ¹Lausanne University Hospital, University of Lausanne, Laussane, Switzerland, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴University of Calgary, Calgary, Canada, ⁵MitogenDx, Calgary, AB, Canada, ⁶MitognDx, Calgary, AB, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Harvard Medical School and Brigham and Women's Hospital, Boston, MA
Background/Purpose: Up to a third of those with suspected SLE progress to definite SLE; however, reliable predictive markers for disease progression remain unknown. Previously, we…
Abstract Number: 2652 • ACR Convergence 2025
Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility
Zsuzsanna McMahan¹, Srinivas Puttapaka², Livia Casciola-Rosen³, Timothy Kaniecki³, Laura Gutierrez³, Su Hong MIng², Philippa Seika² and Subhash Kulkarni⁴, ¹UT Health Houston, Houston, TX, ²BIDMC/Harvard, Boston, MA, ³Johns Hopkins University, Baltimore, MD, ⁴BIDMC, Boston, MA
Background/Purpose: Most patients with systemic sclerosis (SSc) experience gastrointestinal (GI) dysmotility. The enteric nervous system (ENS) regulates GI motility, and its dysfunction causes dysmotility. A…
Abstract Number: L11 • ACR Convergence 2024
Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification
May Choi¹, Farbod Moghaddam¹, Mohammad Sajadi¹, Ann E. Clarke¹, Sasha Bernatsky², Karen Costenbader³, Irene Chen⁴, Murray Urowitz⁵, John Hanly⁶, Caroline Gordon⁷, Sang-Cheol Bae⁸, Juanita Romero-Diaz⁹, Jorge Sanchez-Guerrero¹⁰, Daniel Wallace¹¹, David Isenberg¹², Anisur Rahman¹³, Joan Merrill¹⁴, Paul Fortin¹⁵, Dafna Gladman¹⁶, Ian Bruce¹⁷, Michelle Petri¹⁸, Ellen Ginzler¹⁹, Mary Anne Dooley²⁰, Rosalind Ramsey-Goldman²¹, Susan Manzi²², Andreas Jönsen²³, Graciela Alarcón²⁴, Ronald Van Vollenhoven²⁵, Cynthia Aranow²⁶, Meggan Mackay²⁶, Guillermo Ruiz-Irastorza²⁷, S. Sam Lim²⁸, Murat Inanç²⁹, Kenneth Kalunian³⁰, Soren Jacobsen³¹, Christine Peschken³², Diane Kamen³³, Anca Askanase³⁴, Marvin Fritzler³⁵ and Mina Aminghafari¹, ¹University of Calgary, Calgary, AB, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³Brigham and Women's Hospital/Harvard Medical School, Boston, MA, ⁴UC Berkeley and UCSF, Berkeley, CA, ⁵Self employed, Toronto, ON, Canada, ⁶Dalhousie University, Halifax, NS, Canada, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸Hanyang University Medical Center, Seoul, South Korea, ⁹The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ¹⁰Krembil Research Institute, Toronto, ON, Canada, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, ¹³University College London, London, United Kingdom, ¹⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁵Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, ¹⁶University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁷Queen's University Belfast, Belfast, United Kingdom, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹SUNY Downstate Health Sciences University, New York, NY, ²⁰UNC physician network, Chapel Hill, NC, ²¹Northwestern University, Chicago, IL, ²²Allegheny Health Network, Pittsburgh, PA, ²³Lund University, Lund, Sweden, ²⁴The University of Alabama at Birmingham, Oakland, CA, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Feinstein Institutes for Medical Research, New York, NY, ²⁷Biobizkaia Health Research Institute, Bilbao, Spain, ²⁸Emory University, Atlanta, GA, ²⁹Istanbul University, Istanbul, Turkey, ³⁰UC San Diego, La Jolla, CA, ³¹Rigshospitalet, Copenhagen, Denmark, ³²University of Manitoba, Winnipeg, MB, Canada, ³³Medical University of South Carolina, Johns Island, SC, ³⁴Columbia University Medical Center, New York, NY, ³⁵Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 0308 • ACR Convergence 2024
Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Juan A. Meraz-Ostiz, Aina Puiggròs-Ferrer, Núria Bou, Irene Carrión-Barberà, Jordi Monfort, Carolina Pérez-García, Diana Badenes, Eva Balcells and Anna Pros-Simon, Hospital del Mar, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new…
Abstract Number: 0673 • ACR Convergence 2024
BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients
Yong Yuan¹, Shanzhi He², Wenli Zhang³, Hongyu Zhang⁴, Vincent M DeStefano⁵, Masayuki Wada⁵, Kevin Pinz⁵, Greg Deener⁵, Yu Ma⁶, Min Wang², Fugui Li⁷, Ming Hong¹, Chanjuan Zou², Mingxia Wang², Ling Ding², Yingwen Liang⁸, Yupo Ma⁵ and Weija Wang⁹, ¹Department of Translational Medicine, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ²Department of Rheumatoid Immunology, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ³Department of Hematology, Peking University Shenzhen Hosptial, Shenzhen, China (People's Republic), ⁴Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China (People's Republic), ⁵iCell Gene Therapeutics, Inc., Stony Brook, NY, ⁶iCAR Bio Therapeutics Ltd, Zhongshan, China (People's Republic), ⁷Department of Translational Medicine. Zhongshan people's Hospital, Zhongshan, China (People's Republic), ⁸Department of Translational Medicine, Zhongshan's people Hospital, Zhongshan, China (People's Republic), ⁹Department of Translational Research, Zhongshan people's Hospital, Zhongshan, China (People's Republic)
Background/Purpose: Medication free complete remission (CR) has been elusive in SLE. An open label investigator-initiated trial (IIT) infused SLE/LN patients with a novel cCAR targeting…
Abstract Number: 1161 • ACR Convergence 2024
Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Adriana Miguel-Álvarez¹, luis M Amezcua Guerra², María L Loredo-Mendoza¹, Luis H. Silveira Torre³ and Angélica Vargas Guerrero⁴, ¹Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, ²Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁴Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico
Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…
Abstract Number: 1589 • ACR Convergence 2024
Whole Skin Gene Expression Analysis Identifies Discrete Modules That Differentiate Antinuclear Antibody Subsets in Systemic Sclerosis
Kristina Clark¹, Corrado Campochiaro², Philip Yee³, Emma Derrett-Smith⁴, Voon Ong⁵ and Christopher Denton⁶, ¹University of Oxford, Oxford, United Kingdom, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ³UCL, London, United Kingdom, ⁴University College London Division of Medicine, Birmingham, United Kingdom, ⁵University College London, London, England, United Kingdom, ⁶University College London, Northwood, United Kingdom
Background/Purpose: Hallmark autoantibody reactivities predict different patterns of skin involvement and risk of internal organ involvement. We have asked whether whole skin gene expression may…

« Previous Page
1
…
6
7
8
9
10
…
37
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].